British pharmaceutical company GSK announced Friday that an experimental drug it is developing for patients with advanced or relapsed small-cell lung cancer has delivered promising results in a late-stage clinical study.
The drug, called Ris-Rez, which GSK obtained through a licensing agreement with China’s Hansoh Pharma covering markets outside that country, demonstrated what the company described as “statistically significant and clinically meaningful” improvements in overall survival when compared to standard treatment options.
Ris-Rez is an antibody-drug conjugate, meaning it is designed to deliver treatment directly to cancer cells by targeting a specific protein called B7H3 found on those cells. Beyond small-cell lung cancer, the drug is also being developed to treat other types of tumors, including prostate cancer.
This is not the first time GSK has highlighted promising cancer therapies from its partnership with Hansoh. Back in April, the company said another experimental targeted cancer drug, known as Mo-rez and also licensed from Hansoh, has the potential to become a blockbuster treatment.
